NA
XFOR icon

NewEdge Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

NewEdge Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33
Closed -$132 – 4422
2025
Q4 		$132 Hold
33
– – ﹤0.01% 4152
2025
Q3 		$113 Hold
33
– – ﹤0.01% 4029
2025
Q2 		$63 Hold
33
– – ﹤0.01% 3921
2025
Q1 		$236 Buy
+33
New +$455 ﹤0.01% 3789

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NewEdge Advisors's XFOR Position: Q1 2026 in Review

NewEdge Advisors sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 33 shares — an estimated $132 sold.

NewEdge Advisors first reported a position in XFOR in Q1 2025 and held it in 4 quarters. The position peaked at $236 in Q1 2025. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • NewEdge Advisors reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 33 X4 Pharmaceuticals shares in Q1 2026, an estimated $132.
  • NewEdge Advisors first reported a position in X4 Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • NewEdge Advisors's X4 Pharmaceuticals position peaked at $236 in Q1 2025.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.